09.23.14 iCeutica Receives Key Patent for SoluMatrix Fine Particle Technology Platform
02.24.14 Second Therapeutic Using iCeutica’s SoluMatrix Fine Particle Technology™ Receives FDA Approval
10.18.13 First Therapeutic Using iCeutica’s SoluMatrix™ Technology Receives FDA Approval
10.16.13 iCeutica Appoints Jyrki Mattila, M.D., as Chief Business Officer
09.12.13iCeutica Announces Positive Top-line Phase 1 Results for ICE 1201 Metaxalone Program
09.05.13Investigational Submicron Diclofenac Reduces Use of Opioid Rescue Medication in Post-Surgical Pain in a Phase 3 Study
01.23.13iCeutica Commences Clinical Program for Metaxalone SoluMatrix™
